Arie Apel

Shamir, Z, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.

Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.

Journal: Transplantation and cellular therapy
Published: July 31, 2024

Timing of BNT162b2 vaccine prior to COVID-19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study.

Timing of BNT162b2 vaccine prior to COVID-19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study.

Journal: Cancer medicine
Published: April 18, 2023

Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still's Disease.

Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still's Disease.

Journal: European journal of rheumatology
Published: August 09, 2022

Haematological patients' perception of home transfusions: Effect of the COVID-19 pandemic.

Haematological patients' perception of home transfusions: Effect of the COVID-19 pandemic.

Journal: Vox sanguinis
Published: May 09, 2022

Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.

Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.

Journal: Annals of hematology
Published: March 27, 2022

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.

Journal: American journal of hematology
Published: June 17, 2021

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.

Journal: Transplantation and cellular therapy
Published: May 27, 2021

Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.

Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.

Journal: American journal of hematology
Published: December 29, 2020

Venetoclax is safe and efficacious in relapsed/refractory AML.

Venetoclax is safe and efficacious in relapsed/refractory AML.

Journal: Leukemia & lymphoma
Published: May 19, 2020

CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?

CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?

Journal: Harefuah
Published: November 14, 2019

Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.

Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.

Journal: Annals of hematology
Published: June 23, 2019

Prevalence of Paroxysmal Nocturnal Hemoglobinuria Clones in Myeloproliferative Neoplasm Patients: A Cross-Sectional Study.

Prevalence of Paroxysmal Nocturnal Hemoglobinuria Clones in Myeloproliferative Neoplasm Patients: A Cross-Sectional Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 14, 2019
Showing 1-12 of 22

Last Updated: 09/26/2026